
usd apr pm et
summari compani manufactur scientif analyt equip liquid chromatographi
thermal analysi mass spectrometri product
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan pm stock trade
liquid chromatographi mass spectrometri
market off-set highli competit marketplac
depend unpredict pharmaceut budget
approxim sale pharmaceut custom
produc volatil sale swing life scienc tool
maker pharmaceut budget
manufactur need unexpectedli face larg cut
unanticip drug patent challeng pipelin failur
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra maintain
corpor drop
target
ep estim -- line histor
forward price-to-earnings averag ep vs
consensu lower
ep estim
revenu fell yoy mark
driver major slowdown asia sale
grew flat yoy
sharp drop europ sale
grew fell yoy
sharpli versu
lead yoy drop adjust pre-tax
incom yoy drop per share
basi due net share buyback
last year diverg non-gaap ep
growth yoy due exclus
restructur cost versu
expect reli heavili
buyback restructur adjust
meet ep growth guidanc
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview water corpor specialti measur compani develop tool
liquid chromatographi lc mass spectrometri ms thermal analysi ta tool primarili
serv research develop manufactur tester life materi food scienc
compani also sell softwar platform use oper machin analyz result data well
servic laboratori workflow optim
liquid chromatographi standard scientif techniqu separ identifi constitu
compon variou compound molecular level lc allow research analyz chemic
physic biolog composit materi liquid chromatographi often use tandem
mass spectrometri use elucid structur chemic properti molecul
measur mass molecul convert ion ms also use identifi
quantifi amount specif compound present sampl
thermal analysi tool allow research analyz compound react temperatur chang
especi electr properti chang physic properti fluctuat weight flow
characterist thermal analysi use help research predict compound perform
move laboratori state applic state molecul drug
perform blood rather lab bench suitabl stabil fine
chemic pharmaceut water polym metal viscou liquid use industri applic
consum good health care product better understood thermal analysi
import user product research pharmaceut life scienc
industri scientist use lc ms ta extens analyz compound molecular level
help better understand diseas discov new drug develop manufactur method assur
potenc puriti new pharmaceut tool also use varieti applic
analyz content food beverag nutrit label complianc test water
air sampl meet safeti puriti regul within environment test busi well
applic industri chemic consum product univers research
institut government agenc food drug administr fda
environment protect agenc epa foreign counterpart also frequent user
import aspect busi understand instrument sale vs consum servic
sale instrument perman fixtur laboratori manufactur site come rel
larg up-front cost convers consum lower-cost product use analyz
instrument typic replac regular interv relationship instrument
consum somewhat analog razor razor-blad model custom typic purchas
rel small number instrument continu order larg volum consum
life machin analyz thousand sampl instrument sale often lead recur
softwar servic contract revenu well way singl instrument sale often lead durabl
long-term sale lower-cost product mitig cyclic instrument sale
revenu came instrument servic consum
competit landscap due often high-tech innov natur custom
must also frequent innov product meet evolv custom need stay competit
spent revenu research develop competit
market tool intens rival compet primarili basi product innov
perform reliabl servic price lc ms market competitor includ larg life
scienc tool servic firm shimadzu thermo
fisher scientif thermal analysi market princip competitor includ
netzsch-geraetebau malvern panalyt anton-paar
financi trend sale increas repres three-year
compound annual growth rate compound-annual-growth-rate adjust ep rose
three-year compound-annual-growth-rate grown ep materi faster revenu combin
improv oper margin share count reduct adjust pre-tax incom margin improv
major gain come declin sg expens
margin gross profit margin remain rel constant
respect compani also execut net share repurchas worth
reduc share count three-year period maintain low debt
rel earn net cash posit decemb
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
fairli valu
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
lst sub-industri
next month think among
fastest-grow sub-industri within health
care sector driver earn growth
sub-industri next year
view strong growth public fund
health care research increas
spend biopharmaceut compani
demand growth emerg market
budget nation institut
nih grew rapidli last three year
materi increas fund academ
govern lab turn drive sale
growth mani lst compani suppli
lab nih fy sep budget
increas vs prior year follow
growth fy fy
respect mark major increas
averag increas fy fy
believ growth govern
fund boost sale lst
sub-industri grew rate greater
expect
anoth year robust sale growth
sub-industri although high
aid strong growth nih
addit publicly-fund health care
research expect larg increas privat
biopharmaceut spend also drive
sale growth lst sub-industri
estim total spend
 pharmaceut
 depart research tool softwar
well contract servic clinic drug
trial commerci think
biopharmaceut invest remain
strong year ahead treatment
innov cell gene therapi
develop provid anoth tailwind
sale growth lst sub-industri
beyond biopharmaceut industri
health care research type
prolifer around world particularli
china emerg market rapidli
grow middl class need access
advanc health care turn driven
strong intern sale growth
establish lst compani china
asia-pacif nation particular
estim sub-industri sale
asia-pacif region grew
howev tailwind may moder
somewhat note lst sale
growth region remain strong
estim year-over-year
despit slowdown nearli
like relat slower
econom growth china -china
nevertheless long term think china
major emerg market nation like
india need continu rapidli increas
health care expenditur parallel
grow middl class support
long-term sale growth lst
sub-industri see happen despit
neg impact import/export
tariff limit large-scal
supplier option state-of-the-art lst
product outsid compani
view notabl except
switzerland-bas roch
 life
vs drop
year-to-d april
lst rose gain
base index
five-year market price perform apr
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep buy opinion share corpor
keep target slightli peer
ep estim lead market share
ep vs ahead view sale aid fx benefit
rose strong sale pharmaceut govern end market
respect sale ta product line rose constant
currenc basi instrument sale fell recur sale rose sale india
mass spectrometri product line weaker expect due
soft biomed research believ temporari along chang
within sale team complet expect sale improv
mass spectrometri throughout year sale india advers impact
chang good servic tax gst expect normal
board approv new stock buy-back program addit
remain prior buy-back program /jeffrey loo cfa
corpor rais target
slightli peer ep estim set
ep vs ahead estim sale aid
fx benefit rose broad-bas growth across product
geographi sale pharmaceut end-market rose aid
double-digit growth china rebound india industri
market rose sale govern market rose though note
market volatil guid sale growth mid-singl digit
ep /jeffrey loo cfa
et cfra keep buy opinion share corpor
rais target in-lin
peer forward ep estim rais
ep estim ep
vs ahead estim sale fx benefit rose
broad-bas growth across end-market pharma sale rose
industri government/academ rose see continu
benefit rise global regulatori standard along increas use mass
spectrometri routin workflow process includ food safeti /jeffrey loo
analyst research note compani news
et cfra maintain hold opinion share water corpor
drop target ep
estim -- line histor forward price-to-earnings averag ep
vs consensu lower ep estim
revenu fell yoy mark first
sale declin sinc primari driver major slowdown asia sale
grew flat yoy sharp drop
europ sale grew fell yoy addit
adjust pre-tax margin fell sharpli versu
lead yoy drop adjust pre-tax incom yoy drop
per share basi due net share buyback last year
diverg non-gaap ep growth yoy due exclus
restructur cost versu expect reli
heavili buyback restructur adjust meet ep growth
guidanc /colin scarola
rais target
ep estim slightli five-year averag forward price-to-earnings
expect growth moder year ahead ep vs
ahead estim rais ep estim
revenu growth yoy driven acceler
-- yoy vs china sale growth
continu impress well around yoy cy revenu growth
slow howev expect
modest deceler around despit modest sale
slowdown materi improv oper margin
lower sg expect improv year back robust
 growth continu buyback support ep growth near
given slow sale growth feel less premium
valuat warrant /colin scarola
hold buy lower target
ep estim line five-year averag forward price-to-earnings
ep vs line estim lower ep
estim initi
concern loss sale growth momentum sale growth
fell yoy averag prior four quarter sale
pharmaceut custom total led slowdown yoy growth
versu averag prior four quarter despit slower top-lin
growth still grew adjust ep yoy aid estim bp
improv ebita margin yet buyback drove half ep
gain would like see actual earn growth drive lion share
ep gain expect continu buyback support ep growth
high singl digit given slow revenu growth feel premium
valuat less warrant /colin scarola
et cfra keep buy opinion share corpor
keep target slightli peer
forward ep estim see continu sale
momentum ep vs estim keep
ep estim rais ep estim sale
fx benefit rose repres sequenti improv
sale softer expect particularli india mass
spectrometri line sale mass spectrometri improv driven solid
growth core tandem quadrupol product note
high-resolut mass spectrometri line continu affect soft
biomed research sale india flat anticip improv
expect purchas pattern normal advers
impact chang countri good servic tax sale china
grew mid-teen thermal analysi unit grew aid new
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
